A Questionnaire-based Study to Comprehensively Assess the Status Quo of Rare Disease Patients and Care-givers in China

Xuefeng Li, Meiling Liu, Bingzhe Li, Xiangyu Zhang, Shu Zhang, Zijuan Lu, Jianyong Zhang, Jincheng Zhou, Li OuResearch Square 2021 · DOI

Introduction

Rare diseases, while individually infrequent, represent a significant public health challenge in China, affecting an estimated 16.8 million individuals. Despite the scale of this community, China currently lacks a formal legal definition for rare diseases and a dedicated "Orphan Drug Act" to stimulate the development and accessibility of treatments. This study provides a comprehensive assessment of the "status quo" for these patients and their caregivers, focusing on the diagnostic process, financial burdens, and the psychological toll of living with a rare condition in the current Chinese healthcare landscape.

Methodology

The researchers conducted a cross-sectional study using a detailed 116-question survey distributed via the "Seven Pansy Rare Diseases Platform" and the social media platform Zhihu. The survey captured demographic data, diagnostic history, and financial status. To quantify the impact on quality of life and mental health, five validated instruments were utilized:

  • SF-36: To assess general health across eight domains.
  • PHQ-9 and GAD-7: To screen for depression and generalized anxiety, respectively.
  • PHQ-15: To measure the severity of somatic (physical) symptoms.
  • PSQI: To evaluate sleep quality.

Statistical analysis was performed using general linear models to identify how factors such as age, disease type, and the relationship to the patient influenced these outcomes. The study included 1,959 participants (340 patients and 1,599 caregivers) representing 104 rare diseases.

Results

The Diagnostic Odyssey and Resource Inequality

The findings highlight a significant "diagnostic odyssey." On average, patients experienced a diagnostic delay of 1.4 ± 3.0 years and 1.6 ± 3.8 misdiagnoses while visiting an average of 3.2 ± 2.4 hospitals. A striking 43.8% of diagnoses occurred in just 10 major hospitals, and 42.1% were concentrated in five major cities. This geographic concentration underscores a profound inequality in medical resource distribution, forcing families to travel long distances for specialized care.

Financial and Social Impact

The financial burden is severe; over 12% of families reported medical expenses exceeding 100% of their annual income, necessitating reliance on debt or charity. Employment is also heavily impacted, with only 9.4% of adult patients holding jobs, and nearly 70% of respondents depending entirely on other family members' income.

Psychological Toll on the Family Unit

Both patients and caregivers exhibited significantly poorer health status compared to normative populations. Patients reported moderate depression (average PHQ-9 score of 12.1), while caregivers reported mild depression (average 9.5). Anxiety, somatization, and sleep disorders were prevalent across both groups, indicating that the burden of a rare disease affects the entire family unit. Psychological distress was most acute among patients with severe conditions (e.g., Hemophilia, Dravet syndrome) or those who remained undiagnosed.

Discussion and Policy Recommendations

The study identifies the lack of awareness and legislative support as primary barriers to improving the lives of rare disease patients in China. While the diagnostic delay is shorter than in some Western nations—likely due to the aggressive expansion of newborn screening—the subsequent lack of affordable treatment and social support remains a crisis.

The authors recommend several key policy interventions:

  1. Legislative Action: Enacting a national Orphan Drug Act to incentivize treatment development and regulate the market.
  2. Insurance Reform: Integrating rare disease treatments into national medical insurance to alleviate the catastrophic financial burden.
  3. Resource Decentralization: Improving rare disease awareness among local physicians and creating a centralized information hub to reduce the information asymmetry currently faced by patients.
  4. Social Protections: Strengthening legal protections for the rights of rare disease patients in education and employment to foster social inclusion.

By addressing these systemic gaps, China can better support its 16.8 million rare disease stakeholders and move toward a more equitable healthcare landscape.

Summary updated

Abstract

<title>Abstract</title> <bold>Background</bold>: There are over 16.8 million rare disease patients in China, representing a large community that should not be neglected. To provide a basis for policy-makers to better understand the status quo of rare disease patients and care-givers in China and to devise some new policies, a comprehensive analysis of the status quo, unmet needs, difficulty caused by the rare disease is essential.<bold>Methods</bold>: A questionnaire-based study of patients and care-givers (usually family members) was performed. The questionnaire was composed of 116 questions, such as the diagnosis process, treatment access, financial burden, views on patients’ organizations, and a series of standardized tests to assess the quality of their life, including the SF-36, PHQ-9, PHQ-15, GAD-7, and PSQI. To examine the influence of age, disease type, and relationship to patients on the scores in these tests, statistical analysis with a general linear model was conducted.<bold>Findings</bold>: A total of 1,959 patients and care-givers participated in the survey, representing 104 rare diseases, such as lysosomal storage diseases, hemophilia, and muscular dystrophy diseases. The diagnosis was delayed for 1.4 ± 3.0 years, and patients experienced 1.6 ± 3.8 misdiagnoses between 3.2 ± 2.4 hospitals. The hospitals where diagnoses were made were highly concentrated in 10 large hospitals (43.8%) and 5 big cities (42.1%), indicating a significant inequality of medical resources. The disease often led to difficulty in social life, education, and employment, as well as financial burden that was seldom covered by medical insurance. A battery of standardized tests demonstrated poor health status, depression, somatization, anxiety, and sleeping issues among both patients and care-givers (p&lt;0.05).Statistical analysis of the questionnaire also showed that poor health, anxiety, depression, somatization, and sleeping problems were more prevalent in patients than in care-givers, and more prevalent in more severe diseases (e.g., hemophilia, Dravet) or undiagnosed than in other diseases.<bold>Interpretations</bold>: This study identified the lack of rare disease awareness and legislative support as the major challenge to rare diseases in China, and makes key recommendations for policy-makers, including legislating orphan drug act, raising rare disease awareness, and protecting rights in education and employment.
BibTeX
@inproceedings{li2021questionnaire,
  author = {Xuefeng Li and Meiling Liu and Bingzhe Li and Xiangyu Zhang and Shu Zhang and Zijuan Lu and Jianyong Zhang and Jincheng Zhou and Li Ou},
  title = {{A Questionnaire-based Study to Comprehensively Assess the Status Quo of Rare Disease Patients and Care-givers in China}},
  booktitle = {Research Square},
  year = {2021},
  doi = {10.21203/rs.3.rs-304330/v1},
}
Figure